Department of Pharmacology and Biomedical Sciences, Faculty of Pharmacy and Medical Sciences, University of Petra, Amman, Jordan.
Faculty of Pharmacy, Applied Science University, Amman, Jordan.
Drug Res (Stuttg). 2022 Oct;72(8):466-472. doi: 10.1055/a-1886-2094. Epub 2022 Aug 11.
Coronaviruses are emerging threats for human health, as demonstrated by the ongoing coronavirus disease 2019 (COVID-19) pandemic that is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is closely related to SARS-CoV-1, which was the cause of the 2002-2004 SARS outbreak, but SARS-CoV-1 has been the subject of a relatively limited number of studies. Understanding the potential pathways and molecular targets of SARS-CoV-1 will contribute to current drug repurposing strategies by helping to predict potential drug-disease associations.
A microarray dataset, GSE1739, of 10 SARS patients and 4 healthy controls was downloaded from NCBI's GEO repository, and differential expression was identified using NCBI's GEO2R software. Pathway and enrichment analysis of the differentially expressed genes was carried out using Ingenuity Pathway Analysis and Gene Set Enrichment Analysis, respectively.
Our findings show that the drugs dexamethasone, filgrastim, interferon alfacon-1, and levodopa were among the most significant upstream regulators of differential gene expression in SARS patients, while neutrophil degranulation was the most significantly enriched pathway.
An enhanced understanding of the pathways and molecular targets of SARS-CoV-1 in humans will contribute to current and future drug repurposing strategies, which are an essential tool to combat rapidly emerging health threats.
冠状病毒对人类健康构成了新的威胁，目前正在流行的 2019 年冠状病毒病（COVID-19）就是由严重急性呼吸系统综合征冠状病毒 2（SARS-CoV-2）引起的。SARS-CoV-2 与 SARS-CoV-1 密切相关，后者是 2002-2004 年 SARS 爆发的原因，但 SARS-CoV-1 受到的研究相对较少。了解 SARS-CoV-1 的潜在途径和分子靶标有助于当前的药物重新利用策略，有助于预测潜在的药物-疾病关联。
从 NCBI 的 GEO 存储库中下载了 10 名 SARS 患者和 4 名健康对照者的微阵列数据集 GSE1739，并使用 NCBI 的 GEO2R 软件识别差异表达。使用Ingenuity Pathway Analysis 和 Gene Set Enrichment Analysis 分别对差异表达基因进行通路和富集分析。
我们的研究结果表明，地塞米松、非格司亭、干扰素 alfacon-1 和左旋多巴等药物是 SARS 患者差异基因表达的最显著上游调节剂，而中性粒细胞脱颗粒是最显著富集的途径。
对人类 SARS-CoV-1 的途径和分子靶标的深入了解将有助于当前和未来的药物重新利用策略，这是应对快速出现的健康威胁的重要工具。
